275 related articles for article (PubMed ID: 26071276)
1. A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiency.
Atiq F; van den Bemt PM; Leebeek FW; van Gelder T; Versmissen J
Eur J Clin Pharmacol; 2015 Aug; 71(8):921-9. PubMed ID: 26071276
[TBL] [Abstract][Full Text] [Related]
2. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
Nutescu EA; Spinler SA; Wittkowsky A; Dager WE
Ann Pharmacother; 2009 Jun; 43(6):1064-83. PubMed ID: 19458109
[TBL] [Abstract][Full Text] [Related]
3. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study.
Mahé I; Aghassarian M; Drouet L; Bal Dit-Sollier C; Lacut K; Heilmann JJ; Mottier D; Bergmann JF
Thromb Haemost; 2007 Apr; 97(4):581-6. PubMed ID: 17393021
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
Lim W; Dentali F; Eikelboom JW; Crowther MA
Ann Intern Med; 2006 May; 144(9):673-84. PubMed ID: 16670137
[TBL] [Abstract][Full Text] [Related]
5. Comparative pharmacokinetics of LMWHs.
Samama MM; Gerotziafas GT
Semin Thromb Hemost; 2000; 26 Suppl 1():31-8. PubMed ID: 11011804
[TBL] [Abstract][Full Text] [Related]
6. No accumulation of a prophylactic dose of nadroparin in moderate renal insufficiency.
Atiq F; van den Bemt PM; Leebeek FW; van Gelder T; Versmissen J
Neth J Med; 2015 Oct; 73(8):373-8. PubMed ID: 26478547
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic equivalency of low-molecular-weight heparins.
McCart GM; Kayser SR
Ann Pharmacother; 2002 Jun; 36(6):1042-57. PubMed ID: 12022908
[TBL] [Abstract][Full Text] [Related]
8. [Renal impairment in patients with thromboembolic event: prevalence and clinical implications. A systematic review of the literature].
Wilke T; Wehling M; Amann S; Bauersachs RM; Böttger B
Dtsch Med Wochenschr; 2015 Aug; 140(17):e166-74. PubMed ID: 26306024
[TBL] [Abstract][Full Text] [Related]
9. Safety profile of different low-molecular weight heparins used at therapeutic dose.
Gouin-Thibault I; Pautas E; Siguret V
Drug Saf; 2005; 28(4):333-49. PubMed ID: 15783242
[TBL] [Abstract][Full Text] [Related]
10. Low molecular weight heparins in patients with renal insufficiency.
Symes J
CANNT J; 2008; 18(2):55-61. PubMed ID: 18669012
[TBL] [Abstract][Full Text] [Related]
11. Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency.
Clark NP
Thromb Res; 2008; 123 Suppl 1():S58-61. PubMed ID: 18809206
[TBL] [Abstract][Full Text] [Related]
12. Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients.
Cestac P; Bagheri H; Lapeyre-Mestre M; Sié P; Fouladi A; Maupas E; Léger P; Fontan B; Massip P; Montastruc JL
Drug Saf; 2003; 26(3):197-207. PubMed ID: 12580648
[TBL] [Abstract][Full Text] [Related]
13. Low molecular weight heparins and their clinical applications.
Hao C; Sun M; Wang H; Zhang L; Wang W
Prog Mol Biol Transl Sci; 2019; 163():21-39. PubMed ID: 31030749
[TBL] [Abstract][Full Text] [Related]
14. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
15. Venous thromboembolism prevention with LMWHs in medical and orthopedic surgery patients.
Deitelzweig SB; Vanscoy GJ; Niccolai CS; Rihn TL
Ann Pharmacother; 2003 Mar; 37(3):402-11. PubMed ID: 12639173
[TBL] [Abstract][Full Text] [Related]
16. Low-molecular-weight heparin in patients with renal insufficiency.
Schmid P; Fischer AG; Wuillemin WA
Swiss Med Wkly; 2009 Aug; 139(31-32):438-52. PubMed ID: 19685350
[TBL] [Abstract][Full Text] [Related]
17. Low-molecular-weight heparins for the prevention and treatment of venous thromboembolism.
Ornstein DL; Hong-Dice YG; Papini JR
Mil Med; 2001 Jul; 166(7):593-601. PubMed ID: 11469031
[TBL] [Abstract][Full Text] [Related]
18. Low-molecular-weight heparin in patients with chronic renal insufficiency.
Lim W
Intern Emerg Med; 2008 Dec; 3(4):319-23. PubMed ID: 18563531
[TBL] [Abstract][Full Text] [Related]
19. Use of low-molecular-weight heparin to bridge therapy in obese patients and in patients with renal dysfunction.
George-Phillips KL; Bungard TJ
Pharmacotherapy; 2006 Oct; 26(10):1479-90. PubMed ID: 16999658
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of Certoparin During In Vitro and In Vivo Dialysis.
Krieter DH; Fink S; Dorsch O; Harenberg J; Melzer N; Wanner C; Lemke HD
Artif Organs; 2015 Nov; 39(11):951-9. PubMed ID: 25900127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
